Alphagalileo > Item Display

Therapeutic and Diagnostic Functions of One Antibody for Pancreatic Cancer

24/01/2019 Osaka University

Osaka University researchers base biomarker detection and targeted therapy on the same protein from pancreatic cancer patients

Osaka, Japan – Of all gastrointestinal cancers, pancreatic cancer is one of the most aggressive. Because of this, it has a very low 5-year survival rate of just 5% and a median survival time below 6 months. Additionally, treatment is difficult, with only surgery shown to provide a cure. However, the vast majority of patients have tumors that cannot be removed surgically or their cancer is too advanced or spread too far to be treatable.

Current chemotherapy for pancreatic cancer is ineffective long-term. Therefore, to improve the prognosis and as a novel treatment, Osaka University researchers identified a marker protein that could be used in molecular targeted therapy and companion diagnostics. Such a tool can determine how suitable a treatment is for a specific patient, enabling tailored therapy to be administered.

The team studied CKAP4, a plasma membrane protein that functions as a receptor for the secreted protein DKK1 and promotes tumorigenesis. They found that CKAP4 was released from pancreatic cancer cells in exosomes, which are tiny membranous sacs produced by tumor cells to communicate with each other. An advantage of secreted membranous proteins is that they are fairly simple to detect because of their accessibility, so two related techniques were developed to do just this.

“We generated anti-CKAP4 monoclonal antibodies that we used to develop ELISAs for the detection of CKAP4 released by tumors,” says first author Hirokazu Kimura. “These were successfully able to measure CKAP4 protein in the serum of pancreatic cancer patients, and expression levels were shown to match those determined in the tumors themselves.”

These same monoclonal antibodies had the added advantages of blocking signaling in pancreatic tumor cells and preventing them from proliferating and migrating in the laboratory. The team then analyzed the effects of the antibodies on mouse tumors that had developed from the transplantation of human pancreatic cancer cells. Some of the antibodies inhibited tumor growth and stopped the spread of tumors to the lymph nodes, thus crucially prolonging the life of the mice.

“Our work on developing monoclonal antibody preparations against pancreatic cancer offers the dual benefits of diagnosing and treating the disease,” explains corresponding author Akira Kikuchi. “As a next step, we hope to develop screening methods for patients carrying the CKAP4 antigen biomarker who will benefit from therapeutic interventions using anti-CKAP4 antibodies.”

The article, “CKAP4, a DKK1 receptor, is a biomarker in exosomes derived from pancreatic cancer and a molecular target for therapy” was published in Clinical Cancer Research at DOI:
Article: CKAP4, a DKK1 receptor, is a biomarker in exosomes derived from pancreatic
cancer and a molecular target for therapy
Journal: Clinical Cancer Research
DOI: 10.1158/1078-0432.CCR-18-2124
Authors: Hirokazu Kimura, Hideki Yamamoto, Takeshi Harada, Katsumi Fumoto, Yoshihito Osugi, Ryota Sada, Natsumi Maehara, Hayato Hikita, Soichiro Mori, Hidetoshi Eguchi, Masahito Ikawa, Tetsuo Takehara, and Akira Kikuchi
Funding: Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), Japan Agency for Medical Research and development (AMED)
Attached files
  • Fig.1: DKK1–CKAP4 signaling and application of the anti-CKAP4 antibody. DKK1 and CKAP4 are overexpressed in cancer cells and the PI3 kinase–AKT pathway is activated, promoting cell proliferation. Cancer cells secrete CKAP4 in exosomes, and serum CKAP4 is detected by the anti-CKAP4 antibody as a biomarker of pancreatic cancer. The anti-CKAP4 antibody is also useful in pancreatic cancer therapy. (credit: Osaka University)
  • Fig. 2: Anti-tumor effect of the anti-CKAP4 antibody in a pancreatic cancer model. S2-CP8 pancreatic cancer cells were inoculated subcutaneously to generate a xenograft tumor. The intraperitoneal injection of either gemcitabine, a broad-spectrum antimetabolite and antitumor drug, or anti-CKAP4 antibody inhibited tumor growth. The combination of gemcitabine and anti-CKAP4 produced stronger effects. (credit: Osaka University)
24/01/2019 Osaka University
Regions: Asia, Japan
Keywords: Health, Medical, Science, Life Sciences


We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet
AlphaGalileo is a great source of global research news. I use it regularly.
Robert Lee Hotz, LA Times

We Work Closely With...

  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
Copyright 2021 by DNN Corp Terms Of Use Privacy Statement